Biomed Pharmacother. 1982;36(5):266-9.
One hundred and thirty one patients with duodenal ulcer were treated, in a multicentre controlled trial, with pirenzepine (50 mg three times a day for 4 weeks) or with a placebo, using the same schedule. One hundred had clinical examination and endoscopy at the beginning and at the end of the treatment plus a clinical examination at the end of the second week. The number of symptomatic responses and endoscopic healings was significantly greater in patients receiving pirenzepine than in those receiving the placebo. Complete endoscopic healing was achieved in 62% of the treatment group and 30% of controls after 4 weeks. The only detectable side effect was dryness of the mouth (26% in pirenzepine group vs 10% in controls). It is concluded, in view of its minor side effects, that pirenzepine which appears to be a very specific inhibitor of gastric muscarinic receptors provides physicians with a new, safe and effective treatment of peptic ulcer. It appears to be a good alternative to other gastric antisecretory drugs in the management of such patients.
在一项多中心对照试验中，131例十二指肠溃疡患者按相同方案，分别接受哌仑西平（每日3次，每次50毫克，共4周）或安慰剂治疗。100例患者在治疗开始和结束时接受了临床检查和内镜检查，在第二周结束时还进行了一次临床检查。接受哌仑西平治疗的患者出现症状缓解和内镜愈合的人数明显多于接受安慰剂的患者。4周后，治疗组62%的患者实现了内镜完全愈合，对照组为30%。唯一可检测到的副作用是口干（哌仑西平组为26%，对照组为10%）。鉴于其副作用较小，得出结论：哌仑西平似乎是一种非常特异性的胃毒蕈碱受体抑制剂，为医生提供了一种治疗消化性溃疡的新的、安全有效的方法。在这类患者的治疗中，它似乎是其他胃抗分泌药物的良好替代品。
